Dasatinib (Dasatinib) Generation Targeted Drug

Dasatinib (Dasatinib) is a targeted cancer drug. This is a treatment for chronic myelogenous leukemia (CML). Patients who may have Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL) may also be treated with dasatinib when other treatments no longer respond. Patients can also take dasatinib as part of a clinical trial.

Dasatinib is also a second-generation TKI. It is approved in the United States and the European Union for the treatment of patients with chronic myelogenous leukemia who are resistant or intolerant to imatinib. This drug is a dual SRC-ABL kinase inhibitor that is effective against most clinically relevant BCR-ABL mutations, except for the highly resistant T315I. Chronic myelogenous leukemia is characterized by the presence of the Philadelphia (Ph) chromosome, which is caused by a reciprocal translocation between chromosomes 9 and 22t. This translocation creates two new genes, BCR-ABL and 9q- on 22q- (Ph chromosome). The BCR ABL gene encodes a 210 kD protein with deregulated tyrosine kinase (TK) activity, which is critical for the malignant transformation of chronic myelogenous leukemia.

The original drug of dasatinib has been launched in China and is included in the medical insurance. Currently, reimbursement is only available to eligible patients. Common specifications The price of each box of 50mg*60 tablets may be around RMB 10,000. The original drug overseas is even more expensive. Dasatinib generics are also sold overseas. The ingredients of the drug are basically the same as those sold domestically and abroad, but the price is cheap. For example, the price of a box of 50mg*60 tablets produced by an Indian pharmaceutical factory may be several hundred yuan (the price may fluctuate due to exchange rates).